Quick navigation menu :

  1. Go to the content
  2. Go to main section's menu
  3. Go to Search tool
  4. Go to Help menu
  5. Go to modules
  6. Go to the list of keyboard shortcuts

Help menu :

  1. Sanofi Worldwide |
     
  2. Global Business Websites |
     
  3. Contact us |
  4. Sitemap |
  5. Help
  1. Font size

    Reduce the font size Increase the font size  
 
 

Cardiovascular

Contact us

Sanofi in Egypt

3, El Massaneh St.
Zietoun, Cairo, Egypt
P.O. 1486

Tel.: +202 22860000 - 22860060/1/2
Fax: +202 2282906 - 22824855

Content :

Cardiovascular

Aprovel®

(irbesartan)
Aprovel® belongs to the most recent class of anti-hypertension drugs: angiotensin II receptor antagonists.
Aprovel® has obtained an extension of indication in the treatment of renal disease in patients with high blood pressure and type 2 diabetes, in June 2002 for Europe and September 2002 in the United States.

 

CoAprovel®

CoAprovel

(irbesartan and hydrochlorothiazide)
The association of irbesartan with a diuretic, makes it possible to treat patients whose blood pressure is insufficiently controlled by irbesartan or the diuretic alone with similar tolerance.

 

Tritace®

Tritace

(ramipril)
An ACE inhibitor used to reduce the risk of cardiovascular problems in high-risk patients, to lower blood pressure and help slow the progression of renal disease.

 

Updated September 15, 2006